Sahoo Soumya Ranjan, Das Kuldip, Panda Bharti, Pandey Mamata, Acharya Madhusmita, Meher Purnima, Bhoi Sumitra
Department of Biochemistry, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, IND.
Department of Dermatology, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, IND.
Cureus. 2024 Sep 17;16(9):e69599. doi: 10.7759/cureus.69599. eCollection 2024 Sep.
This study estimated the lipid profile and inflammatory biomarker (interleukin-6, IL-6) levels in patients with psoriasis and explored the association between lipid profiles and inflammatory biomarkers (IL-6) in assessing the severity of the disease.
This cross-sectional study was conducted in the Department of Biochemistry, in association with the Department of Dermatology, at the Veer Surendra Sai Institute of Medical Sciences and Research, Burla, from November 2022 to June 2023. A fully automated analyzer (Cobas C311, Roche Diagnostics, Mannheim, Germany) was used to estimate the lipid profile, while the enzyme-linked immunosorbent assay (Erba, Transasia Bio-medicals Ltd., Mumbai, India) was used to estimate the inflammatory marker (IL-6). Data were analyzed using Statistical Package for the Social Sciences version 21.0 (IBM Corp., Armonk, NY). An unpaired t-test was conducted to examine the relationship between two variables. A p value of <0.05 was considered significant. The correlation among IL-6, lipid profile, and psoriasis area severity index (PASI) score was analyzed using Pearson's correlation coefficient. Quantitative data were expressed as means and standard deviations.
Of the 102 study participants, 68 had psoriasis alone, and 34 had psoriasis with arthritis (psoriatic arthritis, PsA). Higher mean serum concentrations of IL-6, total cholesterol (TC), low-density lipoprotein, and triglycerides were found in patients with PsA compared to those with psoriasis alone. In patients with PsA, TC and IL-6 showed a strong positive correlation with the PASI score. In contrast, high-density lipoprotein showed a negative correlation with PASI (r = -0.036, p < 0.05).
In conclusion, our study revealed lipid profile abnormalities and increased IL-6 activity in PsA patients. By measuring inflammatory markers (IL-6) and lipid profiles early in the disease process, we can employ preventive strategies to better manage and improve survival and quality of life in patients with psoriasis.
本研究评估了银屑病患者的血脂谱和炎症生物标志物（白细胞介素-6，IL-6）水平，并探讨了血脂谱与炎症生物标志物（IL-6）在评估疾病严重程度方面的关联。
本横断面研究于2022年11月至2023年6月在伯拉维尔·苏伦德拉·赛义德医学科学与研究学院生物化学系与皮肤科联合开展。使用全自动分析仪（Cobas C311，罗氏诊断公司，德国曼海姆）评估血脂谱，同时使用酶联免疫吸附测定法（Erba，印度孟买Transasia生物医学有限公司）评估炎症标志物（IL-6）。使用社会科学统计软件包第21.0版（IBM公司，纽约州阿蒙克）对数据进行分析。进行独立样本t检验以检查两个变量之间的关系。p值<0.05被认为具有统计学意义。使用Pearson相关系数分析IL-6、血脂谱和银屑病面积严重程度指数（PASI）评分之间的相关性。定量数据以均值和标准差表示。
在102名研究参与者中，68人仅患有银屑病，34人患有银屑病伴关节炎（银屑病关节炎，PsA）。与仅患有银屑病的患者相比，PsA患者的IL-6、总胆固醇（TC）、低密度脂蛋白和甘油三酯的平均血清浓度更高。在PsA患者中，TC和IL-6与PASI评分呈强正相关。相比之下，高密度脂蛋白与PASI呈负相关（r = -0.036，p < 0.05）。
总之，我们的研究揭示了PsA患者存在血脂谱异常和IL-6活性增加。通过在疾病过程早期测量炎症标志物（IL-6）和血脂谱，我们可以采用预防策略来更好地管理和改善银屑病患者的生存率和生活质量。
